Advertisement

Pharmacy World and Science

, Volume 20, Issue 4, pp 161–172 | Cite as

Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors.

  • Virginie M.M. Herben
  • Jos H. Beijnen
  • Wim W. ten Bokkel Huinink
  • Jan H.M. Schellens
Article

Abstract

In this review the clinical pharmacokinetics of camptothecin topoisomerase I inhibitors, an important new class of anticancer drugs, is discussed. Two prototypes, topotecan and irinotecan, are currently marketed in many European countries and the USA for the treatment of patients with ovarian and colorectal cancer, respectively. Other camptothecin derivatives, including lurtotecan, 9‐aminocamptothecin (9‐AC) and 9‐nitrocamptothecin (9‐NC), are at different stages of clinical development. The common property of camptothecin analogues is their action against DNA topoisomerase I, but beyond this similarity the compounds differ widely in terms of antitumour efficacy, pharmacology, pharmacokinetics and metabolism. We review chemistry, mechanism of action, stability and bioanalysis of the camptothecins. Dosage and administration, status of clinical application, pharmacokinetics, pharmacodynamics and drug interactions are discussed.

Camptothecin Clinical pharmacokinetics Irinotecan Topoisomerase I inhibitors Topotecan 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, Sim GA. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumour inhibitor from Camptotheca acuminata. J Am Chem Soc 1966;88:3888-90.Google Scholar
  2. 2.
    Govindachari TR, Visnawathan N. Alkaloids of Mappia foedita. Phytochemistry 1972;11:3529-31.Google Scholar
  3. 3.
    Gottlieb JA, Guarino AM, Call JB, Oliverio VT, Block JB. Preliminary pharmacologic and clinical evaluation of camptothecin sodium. Cancer Chemother Rep 1970;54:461-70.PubMedGoogle Scholar
  4. 4.
    Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 1972;56:95-7.PubMedGoogle Scholar
  5. 5.
    Muggia FM, Creaven PJ, Hansen HH, Cohen MH, Selawry OS. Phase I clinical trial of weekly and daily treatment with camptothecin: correlation with preclinical studies. Cancer Chemother Rep 1972;56:515-21.PubMedGoogle Scholar
  6. 6.
    Hsiang Y-H, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985;260:14873-5.PubMedGoogle Scholar
  7. 7.
    Hsiang Y-H, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988;48:1722-6.PubMedGoogle Scholar
  8. 8.
    Tanizawa A, Fujimori A, Fujimori Y, Pommier Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 1994;86:836-42.PubMedGoogle Scholar
  9. 9.
    Natelson EA, Giovanella BC, Verschraegen CF, Fehir KM, De Ipolyi PD, Harris N, Stehlin JS. Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents. Ann NY Acad Sci 1996;803:224-30.PubMedGoogle Scholar
  10. 10.
    Rothenberg ML. Topoisomerase I inhibitors: review and update. Ann Oncol 1997;8:837-55.PubMedGoogle Scholar
  11. 11.
    Carmichael J, Ozols RF. Topotecan, an active new antineoplastic agent: review and current status. Exp Opin Invest Drugs 1997;6:593-608.Google Scholar
  12. 12.
    O'Reilly S, Rowinsky EK. The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996. Crit Rev Oncol/Hematol 1996;24:47-70.Google Scholar
  13. 13.
    Jaxel C, Kohn KW, Wani MC, Wall ME, Pommier Y. Structureactivity study of the actions of camptothecin derivatives on mammalian topoisomerase I. Evidence of a specific receptor site and for a relation to antitumor activity. Cancer Res 1989;49:1465-9.PubMedGoogle Scholar
  14. 14.
    Hsiang Y-H, Liu LF, Wall ME, et al. DNA topoisomerase Imediated DNA cleavage and cytotoxicity of camptothecin analogs. Cancer Res 1989;49:4385-9.PubMedGoogle Scholar
  15. 15.
    Hertzberg RP, Caranfa MJ, Holden KG, Jakas DR, Gallagher G, Mattern MR, et al. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 1989;32:715-20.PubMedGoogle Scholar
  16. 16.
    Pommier Y, Jaxel C, Kerrigan D, Kohn KW. Structure-activity relationship of topoisomerase I inhibition by camptothecin derivatives: Evidence for the existence of a ternary complex. In: Potmesil M, Kohn KW, eds. DNA topoisomerases in cancer. New York: Oxford University Press, 1991:121-32.Google Scholar
  17. 17.
    Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoismerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989;49:5077-82.PubMedGoogle Scholar
  18. 18.
    Burris III HA, Hanauske AR, Johnson RK, Marshall MH, Kuhn JG, Hilsenbeck SG, Von Hoff DD. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units. J Natl Cancer Inst 1992;84:1816-20.PubMedGoogle Scholar
  19. 19.
    Supko JG, Plowman J, Dyker DJ, Zaharko DS. Relationship between the schedule dependence of 9-amino-20(S)-camptothecin (AC; NSC 603071) antitumor activity in mice and its plasma pharmacokinetics. Proc Am Ass Cancer Res 1992;33:432.Google Scholar
  20. 20.
    Underberg WJM, Goossen RMJ, Smith BR. Equilibrium kinetics of the new experimental anti-tumour compound SK&F 104864-A in aqueous solution. J Pharm Biomed Anal 1990;8:681-3.PubMedGoogle Scholar
  21. 21.
    Fassberg J, Stella VJ. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sc 1992;81:676-84.PubMedGoogle Scholar
  22. 22.
    Burke TG, Munshi CB, Mi Z. The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs. J Pharm Sci 1995;84:518-9.PubMedGoogle Scholar
  23. 23.
    Beijnen JH, Smith BR, Keijer WJ, Van Gijn R, Ten Bokkel Huinink WW, Vlasveld LTh, et al. High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma. J Pharm Biomed Anal 1990;8:789-94.PubMedGoogle Scholar
  24. 24.
    Rosing H, Doyle E, Davies BE, Beijnen JH. High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma. J Chrom B 1995;668:107-11.Google Scholar
  25. 25.
    Supko JG, Malspeis L. Liquid chromatographic analysis of 9-aminocamptothecin in plasma monitored by fluorescence induced upon postcolumn acidification. J Liq Chrom 1992;15:3261-83.Google Scholar
  26. 26.
    Rivory LP, Robert J. Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma. J Chrom B 1994;661:133-41.Google Scholar
  27. 27.
    Van Warmerdam LJC, Creemers GJ, Rodenhuis S, Rosing H, De Boer-Dennert M, Schellens JHM, et al. Pharmacokinetics and pharmacodynamics of topotecan administered at a daily times five schedule in phase II clinical trials using a limited sampling procedure. Cancer Chemother Pharmacol 1996;38:254-60.PubMedGoogle Scholar
  28. 28.
    Ten Bokkel Huinink WW, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;16:2183-93.Google Scholar
  29. 29.
    Ardizzoni A, Hansen HH, Dombernowsky P, Kaplan S, Postmus PE, Gamucci T, et al. Phase II study of topotecan in refractory and sensitive small cell lung cancer (SCLC). Eur J Cancer 1995;31A:S19.Google Scholar
  30. 30.
    Schiller JH, Von Pawel J, Clarke P, et al. Preliminary results of a reandomized phase II trial of topotecan (T) versus CAV as second-line therapy of small-cell lung cancer (SCLC). 8th World Conference on Lung Cancer, Dublin, Ireland. Lung Cancer 1997;18:13.Google Scholar
  31. 31.
    Saltz L, Sirott M, Young C, Tong W, Niedzwiecki D, Tzy-Jyun Y, et al. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst 1993;85:1499-1507.PubMedGoogle Scholar
  32. 32.
    Verweij J, Lund B, Beijnen J, Planting A, De Boer-Dennert M, Koier I, et al. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann Oncol 1993;4:673-8.PubMedGoogle Scholar
  33. 33.
    Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, et al. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 1994;12:553-9.PubMedGoogle Scholar
  34. 34.
    Oostweegel LMM, Van Warmerdam LJC, Schot M, Dubbelman AC, Ten Bokkel Huinink WW, Beijnen JH. Extravasation of topotecan, a report of two cases. J Oncol Pharm Pract 1997;3:115-6.Google Scholar
  35. 35.
    Herben VMM, Ten Bokkel Huinink WW, Beijnen JH. Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 1996;31:85-102.PubMedGoogle Scholar
  36. 36.
    Wall JG, Burris HA III, Von Hoff DD, Rodrigues G, Kneuper-Hall R, Shaffer D, et al. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anticancer Drugs 1992;3:337-45.PubMedGoogle Scholar
  37. 37.
    Van Warmerdam LJC, Verweij J, Schellens JHM, Rosing H, Davies BE, De Boer-Dennert M, et al. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother Pharmacol 1995;35:237-45.PubMedGoogle Scholar
  38. 38.
    Munshi CB, Mi Z, Burke TG. The biophysics underlying the favorable stability of the topotecan anticancer drug in human blood. Proc Am Ass Cancer Res 1995;36:444.Google Scholar
  39. 39.
    Cole DE, Blaney SM, Balis FM. Topotecan in physiologic fluids: depot of active drug in red blood cells. Proc Am Ass Cancer Res 1995;36:363.Google Scholar
  40. 40.
    Baker SD, Heideman RL, Crom WR, Kuttesch JF, Gajjar A, Stewart CF. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemother Pharmacol 1996;37:195-202.PubMedGoogle Scholar
  41. 41.
    Van Warmerdam LJC, Rosing H, Ten Bokkel Huinink WW, Maes RAA, Beijnen JH. Do topotecan concentrations in saliva reflect plasma concentrations? J Oncol Pharm Practice 1995;1:41-5.Google Scholar
  42. 42.
    Herben VMM, Ten Bokkel Huinink WW, Dubbelman AC, Mandjes IAM, Groot Y, Van Zomeren DM, Beijnen JH. Phase I and pharmacologic study of sequential intravenous topotecan and oral etoposide. Br J Cancer 1997;76:1500-8.PubMedGoogle Scholar
  43. 43.
    Schellens JHM, Creemers GJ, Beijnen JH, Rosing H, De Boer-Dennert M, McDonald M, et al. Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br J Cancer 1996;73:1268-71.PubMedGoogle Scholar
  44. 44.
    Gerrits CJH, Burris H, Schellens JHM, Planting AST, Van der Burg MEL, Rodrigues GI, et al. Five days of oral topotecan (Hycamtin®), a phase I and pharmacologic study in adult patients with solid tumors. Submitted for publication.Google Scholar
  45. 45.
    Anonymous. Prescribing information HycamtinJ, SmithKline Beecham 1997.Google Scholar
  46. 46.
    Borkowski JM, Duerr M, Donehower RC, Rowinsky EK, Chen T-L, Ettinger DS, et al. Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data. Cancer Chemother Pharmacol 1994;33:493-6.PubMedGoogle Scholar
  47. 47.
    O'Reilly S, Rowinsky EK, Slichenmyer W, Donehower RC, Forastiere AA, Ettinger DS, et al. Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol 1996;14:3062-73.PubMedGoogle Scholar
  48. 48.
    O'Reilly S, Rowinsky EK, Slichenmyer W, Donehower RC, Forastiere AA, Ettinger DS, et al. Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function. J Natl Cancer Inst 1996;88:817-24.PubMedGoogle Scholar
  49. 49.
    Anonymous. Hycamtin, topotecan for the management of advanced ovarian cancer. Product monograph, SmithKline Beecham Pharmaceuticals 1996.Google Scholar
  50. 50.
    Zamboni WC, Gajjar AJ, Heideman RL, Beijnen JH, Rosing H, Houghton PJ, et al. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clin Cancer Res 1998, in press.Google Scholar
  51. 51.
    Rowinsky EK, Kaufmann SH, Baker SD, Grochow LB, Chen TL, Peereboom D, et al. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. J Clin Oncol 1996;14:3074-84.PubMedGoogle Scholar
  52. 52.
    Grochow LB, Rowinsky EK, Johnson R, Ludeman S, Kaufmann SH, McCabe FL, et al. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab Dispos 1992;20:706-13.PubMedGoogle Scholar
  53. 53.
    Haas NB, La Creta FP, Walczak J, Hudes GR, Brennan JM, Ozols RF, O'Dwyer PJ. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Cancer Res 1994;54:1220-6.PubMedGoogle Scholar
  54. 54.
    Bissery MC, Mathieu-Boué A, Lavelle F. Experimental antitumor activity of CPT-11 in vitro and in vivo. Ann Oncol 1992;3 (suppl 1):82.Google Scholar
  55. 55.
    Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997;15:251-60.PubMedGoogle Scholar
  56. 56.
    Shimada Y, Yashino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 1993;11:909-13.PubMedGoogle Scholar
  57. 57.
    Rothenberg ML, Eckardt JR, Kuhn JG, Burris III HA, Nelson J, Hilsenbeck SG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996;14:1128-35.PubMedGoogle Scholar
  58. 58.
    Pitot HC, Wender DB, O'Connell MJ, Schroeder G, Goldberg RM, Rubin J, et al. Phase II trial of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 1997;15:2910-9.PubMedGoogle Scholar
  59. 59.
    Abigerges D, Chabot GG, Armand J-P, Hérait P, Gouyette A, Gandia D, Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995;13:210-21.PubMedGoogle Scholar
  60. 60.
    De Forni M, Bugat R, Chabot GG, Culine S, Extra J-M, Gouyette A, et al. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan administered on a weeky schedule in cancer patients. Cancer Res 1994;54:4347-54.PubMedGoogle Scholar
  61. 61.
    Rothenberg ML, Kuhn JG, Burris III HA, Nelson J, Eckardt JR, Tristan-Morales M, et al. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 1993;11:2194-204.PubMedGoogle Scholar
  62. 62.
    Rowinsky EK, Grochow LB, Ettinger DS, Sartorius SE, Lubejko BG, Chen T-L, et al. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 1994;54:427-36.PubMedGoogle Scholar
  63. 63.
    Sasaki Y, Yoshida Y, Sudoh K, Hakusui H, Fujii H, Ohtsu T, et al. Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11. Jpn J Cancer Res 1995;86:111-6.PubMedGoogle Scholar
  64. 64.
    Rivory PL, Chatelut E, Canal P, Mathieu-Boué A, Robert J. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients. Cancer Res 1994;54:6330-3.PubMedGoogle Scholar
  65. 65.
    Chabot GG, Abigerges D, Catimel G, Culine S, de Forni M, Extra J-M, et al. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 1995;6:141-51.PubMedGoogle Scholar
  66. 66.
    Herben V, Schellens J, Swart M, Gruia G, Beijnen J, Ten Bokkel Huinink WW. Phase I and pharmacokinetic (PK) study of irinotecan (CPT11) with a prolonged (14 D) infusion schedule. Proc Am Soc Clin Oncol 1997;16:201a.Google Scholar
  67. 67.
    Zamboni WC, Crom WR, Houghton PJ, Thompson JD, Stewart CF. Plasma protein binding of SN-38: the active metabolite of irinotecan. Pharmacotherapy 1996;16:500.Google Scholar
  68. 68.
    Takahashi T, Fujiwara Y, Sumiyoshi H, Miyazaki M, Elisna S, Oguri T, et al. Salivary drug monitoring of irinotecan (CPT-11 and its active metabolite (SN-38) in cancer patients. Cancer Chemother Pharmacol 1997;40:449-52.PubMedGoogle Scholar
  69. 69.
    Lokiec F, Canal P, Gay C, Chatelut E, Armand J-P, Roché H, Bugat R, Gonçalvès E, Mathieu-Boué A. Pharmacokinetics of irinotecan and its metabolites in human blood, bile and urine. Cancer Chemother Pharmacol 1995;36:79-82.PubMedGoogle Scholar
  70. 70.
    Tsuji T, Kaneda N, Kado K, Yokokura T, Yoshimoto T, Tsuru, D. CPT-11 converting enzyme from rat serum: purification and some properties. J Pharmacobio-Dyn 1991;14:341-9.PubMedGoogle Scholar
  71. 71.
    Rivory PL, Robert J. Identification and kinetics of a ß-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemother Pharmacol 1995;36:176-9.PubMedGoogle Scholar
  72. 72.
    Iyer L, King C, Tephly T, Ratain MJ. UGT isoform 1.1 (UGT*1.1) glucuronidates SN-38, the active metabolite of irinotecan. Proc Am Soc Clin Oncol 1997;16:201a.Google Scholar
  73. 73.
    Canal P, Gay C, C, Dezeuze A, Douillard JY, Bugat R, Brunet R, et al. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. J Clin Oncol 1996;14:2688-95.PubMedGoogle Scholar
  74. 74.
    Kaneda N, Nagata H, Furuta T, and Yokokura T. Metabolism and pharmacokinetics of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica 1991;21:1159-69.PubMedGoogle Scholar
  75. 75.
    Rivory LP, Riou JF, Haaz MC, Sable S, Vuilhorgne M, Commerçon A, et al. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res 1996;56:3689-94.PubMedGoogle Scholar
  76. 76.
    Lokiec F, Monegier du Sorbier B, Sanderink GJ. Irinotecan (CPT-11) metabolites in human bile and urine. Clin Cancer Res 1996;2:1943-9.PubMedGoogle Scholar
  77. 77.
    Rivory LP, Haaz M-C, Canal P, Lokiec F, Armand J-P, Robert J. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. Clin Cancer Res 1997;3;1261-6.PubMedGoogle Scholar
  78. 78.
    Wasserman E, Myara A, Lokiec F, Goldwasser F, Trivin F, Mahjoubi M, et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol 1997;8:1049-51.PubMedGoogle Scholar
  79. 79.
    Schaaf L, Ichhpurani N, Elfring G, Wolf D, Rothenberg M, Von Hoff D. Influence of age on the pharmacokinetics of irinotecan (CPT-11) and its metabolites, SN-38 and SN-38 glucuronide (SN-38G), in patients with prevously treated colorectal cancer. Proc Am Soc Clin Oncol 1997;16:202a.Google Scholar
  80. 80.
    Ratain MJ, Mick R, Gupta E, Lestingi TM, Schilsky RL, Vokes EE. Prospective evaluation of the effect of race and gender on irinotecan (CPT-11) pharmacokinetics and intestinal toxicity. Proc Am Soc Clin Oncol 1996;15:472.Google Scholar
  81. 81.
    Rivory LP, Bowles MR, Robert J, Pond SM. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38) by human liver carboxylesterase. Biochem Pharmacol 1996;52:1103-11.PubMedGoogle Scholar
  82. 82.
    Haaz MC, Rivory LP, Riché C, Vernillet L, Robert J. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: Participation of cytochrome P-450 3A and drug interactions. Cancer Res 1998;58:468-72.PubMedGoogle Scholar
  83. 83.
    Gupta E, Wang X, Ramirez J, Ratain MJ. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother Pharmacol 1997;39:440-4.PubMedGoogle Scholar
  84. 84.
    Gupta E, Mick R, Ramirez J, Wang X, Lestingi TM, Vokes EE, Ratain MJ. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 1997;15:1502-10.PubMedGoogle Scholar
  85. 85.
    Fagbemi S, Iyer L, Mani S, Vogelzang NJ, Cohn H, Fasanmade A, Ratain MJ. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered with cyclosporine A. Proc Am Soc Clin Oncol 1997;16:219a.Google Scholar
  86. 86.
    Sasaki Y, Ohtsu A, Shimada Y, Ono K, Saijo N. Simultaneous administration of CPT-11 and fluoruracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer [letter]. J Natl Cancer Inst 1994;86:1096-8.PubMedGoogle Scholar
  87. 87.
    Saltz LB, Kanowitz J, Kemeny NE, Schaaf L, Spriggs D, Staton BA, et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil and leucovorin in patients with advanced solid tumors. J Clin Oncol 1996;14:2959-67.PubMedGoogle Scholar
  88. 88.
    Lokiec F, Wasserman E, Santoni J, Mahjoubi M, Misset JL Cvitkovic E. Pharmacokinetics of the irinotecan/oxaliplatin combination: preliminary data of an ongoing phase I trial. Proc Am Soc Clin Oncol 1997;16:203a.Google Scholar
  89. 89.
    Sasaki Y, Hakusui, Mizuno S, Morita M, Miya T, Eguchi K, et al. A pharmacokinetic and pharmacodynamic analyis of CPT-11 and its active metabolite SN-38. Jpn J Cancer Res 1995;86:101-10.PubMedGoogle Scholar
  90. 90.
    Kudoh S, Fukuoka M, Masuda N, Yoshikawa A, Kusunoki Y, Matsui K, et al. Relationship between the pharmacokinetics of irinotecan and diarrhoea duing combination chemotherapy with cisplatin. Jpn J Cancer Res 1995;86:406-13.PubMedGoogle Scholar
  91. 91.
    Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994;54:3723-5.PubMedGoogle Scholar
  92. 92.
    Gerrits CJ, Creemers GJ, Schellens JH, Wissel P, Planting AS, Kunka R, et al. Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x5 intravenous administration. Br J Cancer 1996;73:744-50.PubMedGoogle Scholar
  93. 93.
    O'Dwyer P, Cassidy J, Kunka R, Pas-Arez L, Kaye S, DePee S, et al. Phase I trial of GG211, a new topoisomerase inhibitor, using a 72 hour continuous infusion. Proc Am Soc Clin Oncol 1995;14:471.Google Scholar
  94. 94.
    Wanders J. The experience of the EORTC early clinical trials group (ECSG) with GW211 in solid tumors. The Eighth Conference on DNA Topoisomerases in Therapy, Amsterdam, 15-17 october 1997;72.Google Scholar
  95. 95.
    Schellens JHM, Pritchard JF, Gerrits CJH, Wissel PS, Beranek P, Creemers GJ, et al. Absolute oral bioavailability of the topoisomerase I inhibitor GG211. The Sixth Conference on DNA Topoisomerases in Therapy, Amsterdam, 6-8 september 1995;87.Google Scholar
  96. 96.
    Rubin E, Wood V, Bharti A, Trites D, Lynch C, Hurwitz S, et al. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin Cancer Res 1995;1:269-76.PubMedGoogle Scholar
  97. 97.
    Dahut W, Harold N, Takimoto C, Allegra C, Chen A, Hamilton M, et al. Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. J Clin Oncol 1996;14:1236-44.PubMedGoogle Scholar
  98. 98.
    Takimoto CH, Dahut W, Marino MT, Nakashima H, Liang MD, Harold N, et al. Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients. J Clin Oncol 1997;15(4):1492-501.PubMedGoogle Scholar
  99. 99.
    Liang MD, Dahut W, Quinn MF, Harold N, Arbuck SG, Chen A, et al. Preclinical and clinical studies of a new colloidal dispersion formulation of 9-aminocamptothecin. Proc Am Ass Cancer Res 1996;37:432.Google Scholar
  100. 100.
    Mani S, Iyer L, Janisch L, Wang X, Fleming GF, Schilsky RL, Ratain MJ. Phase I clinical and pharmacokinetic (PK) study of oral 9-aminocamptothecin (9-AC) (NSC-603071). Proc Am Soc Clin Oncol 1997;16:201a.Google Scholar
  101. 101.
    Sparreboom A, Stoter G, Loos WJ, Nooter K, Punt CJA, Colajori E, Verweij J. Oral bioavailability of 9-aminocamptothecin in adult patients with solid tumors. Proc Am Ass Cancer Res 1997;38:75.Google Scholar
  102. 102.
    Minami H, Mick R, Vokes EE, Ratain MJ. Pharmacodynamic models for leukopenia and thrombocytopenia of 9-aminocamptothecin. Proc Am Soc Clin Oncol 1996;15:179.Google Scholar
  103. 103.
    Grossman SA, Hochberg F, Fisher J, Chen TL, Kim L, Gregory R, et al. Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. Proc Am Soc Clin Oncol 1997;16:389a.Google Scholar
  104. 104.
    Hinz HR, Harris NJ, Natelson EA, Giovanella BC. Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20(S)-camptothecin to 9-amino-20(S)-camptothecin in humans, dogs and mice. Cancer Res 1994;34:3096-100.Google Scholar
  105. 105.
    Verschraegen CF, Natelson E, Giovanella BC, Kavanagh JJ, Kudelka AP, Freedman RS, et al. A phase I and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anti-Cancer Drugs 1998;9:36-44.PubMedGoogle Scholar
  106. 106.
    Verschraegen CF, Harris N, Steger M, Kavanagh J, Kudelka A, Giovanella B. Pharmacology study of multiple oral doses of 9-nitrocamptothecin (9NC). Proc Am Ass Cancer Res 1997;38:74.Google Scholar
  107. 107.
    Verschraegen CF, Giovanella BC, Harris N, Natelson E, Kavanagh JJ, Kudelka AP, et al. Pharmacodynamics and in vivo serum concentrations of the total drug and the lactone form of 9-nitrocamptothecin (9-NC) administered orally. Proc Am Ass Cancer Res 1996;37:180.Google Scholar
  108. 108.
    Toppmeyer D, Gupta E, Saleem A, Zamek R, Much J, Ibrahim J, et al. A phase I pharmacokinetic and pharmacodynamic study of camptothecin (CPT) and etoposide (E) in patients with advanced malignancies. Proc Am Soc Clin Oncol 1997;16:203a.Google Scholar
  109. 109.
    Gupta E, Ahmad FY, Cook TJ, Saleem A, Li X-G, Zamek R, et al. Optimizing administration of oral camptothecins: intestinal permeability of lactone and total 20(S) camptothecin (CPT). Proc Am Soc Clin Oncol 1997;16:237a.Google Scholar
  110. 110.
    Takiguchi S, Kumazawa E, Shimazoe T, Tohgo A, Kono A. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice. Jpn J Cancer Res 1997;88:760-9.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1998

Authors and Affiliations

  • Virginie M.M. Herben
    • 1
  • Jos H. Beijnen
    • 1
  • Wim W. ten Bokkel Huinink
    • 2
  • Jan H.M. Schellens
    • 2
  1. 1.Department of Pharmacy and PharmacologyThe Netherlands Cancer Institute/Slotervaart HospitalAmsterdamThe Netherlands
  2. 2.Department of Medical OncologyThe Netherlands Cancer Institute/Antoni van LeeuwenhoekhuisAmsterdamThe Netherlands

Personalised recommendations